ACVC Premium Access

All stented patients with atrial fibrillation, stable one year after intervention, should be managed with oral anticoagulants, without antiplatelets - PRO.

Presentation

About the speaker

Professor Raffaele De Caterina

University Hospital of Pisa, Pisa (Italy)
25 presentations
1 follower

9 more presentations in this session

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - PRO.

Speaker: Doctor A. Rubboli (Ravenna, IT)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.

Speaker: Professor R. Storey (Sheffield, GB)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal PRO.

Speaker: Doctor A. Rubboli (Ravenna, IT)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.

Speaker: Professor R. Storey (Sheffield, GB)

Thumbnail

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough: Chairpersons conclusion

Thumbnail

Access the full session

Controversies on anticoagulants post-MI antithrombotic treatment

Speakers: Professor R. De Caterina, Doctor A. Rubboli, Professor R. Storey, Doctor A. Rubboli, Professor R. Storey
Thumbnail

About the event

Image

Acute Cardiovascular Care 2018

3 March - 5 March 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk